These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 38288635)
1. PD-L1 expression in resected lung adenocarcinoma: prevalence and prognostic significance in relation to the IASLC grading system. Hwang S; Hong TH; Kim HK; Cho J; Lee G; Choi S; Park S; Lee SH; Lee Y; Jeon YJ; Lee J; Park SY; Cho JH; Choi YS; Kim J; Zo JI; Shim YM; Choi YL Histopathology; 2024 May; 84(6):1013-1023. PubMed ID: 38288635 [TBL] [Abstract][Full Text] [Related]
2. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma. Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407 [TBL] [Abstract][Full Text] [Related]
3. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells. Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548 [No Abstract] [Full Text] [Related]
5. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer. Kim H; Kwon HJ; Park SY; Park Y; Park E; Chung JH PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861 [TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031 [TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of programmed death ligand 1 expression in resected lung adenocarcinoma: a systematic review and meta-analysis. Chen D; Mao Y; Ding Q; Wang W; Zhu F; Chen C; Chen Y Eur J Cardiothorac Surg; 2020 Nov; 58(5):888-898. PubMed ID: 32596715 [TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma. Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160 [TBL] [Abstract][Full Text] [Related]
10. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. Song Z; Yu X; Cheng G; Zhang Y J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566 [TBL] [Abstract][Full Text] [Related]
11. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer. Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750 [TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. Takamori S; Takada K; Azuma K; Jogo T; Shimokawa M; Toyokawa G; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y Ann Surg Oncol; 2019 Jun; 26(6):1916-1924. PubMed ID: 30815801 [TBL] [Abstract][Full Text] [Related]
14. The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma. Wu S; Shi X; Sun J; Liu Y; Luo Y; Liang Z; Wang J; Zeng X Oncotarget; 2017 Mar; 8(10):16421-16429. PubMed ID: 28145884 [TBL] [Abstract][Full Text] [Related]
15. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662 [TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma. Kozuma Y; Takada K; Toyokawa G; Kohashi K; Shimokawa M; Hirai F; Tagawa T; Okamoto T; Oda Y; Maehara Y Eur J Cancer; 2018 Sep; 101():20-29. PubMed ID: 30014971 [TBL] [Abstract][Full Text] [Related]
17. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153 [TBL] [Abstract][Full Text] [Related]
18. PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma. Zaric B; Brcic L; Buder A; Brandstetter A; Buresch JO; Traint S; Kovacevic T; Stojsic V; Perin B; Pirker R; Filipits M Clin Lung Cancer; 2018 Nov; 19(6):e957-e963. PubMed ID: 30197262 [TBL] [Abstract][Full Text] [Related]
19. Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients. Qin T; Xia J; Liu S; Wang J; Liu H; Zhang Y; Jia Y; Li K Thorac Cancer; 2020 May; 11(5):1139-1148. PubMed ID: 32154654 [TBL] [Abstract][Full Text] [Related]
20. Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early-stage lung adenocarcinoma. Hong TH; Hwang S; Choi YL; Lee G; Park S; Ahn MJ; Lee Y; Jeon YJ; Lee J; Shin S; Park SY; Cho JH; Choi YS; Kim J; Shim YM; Cho J; Kim HK Histopathology; 2023 Aug; 83(2):168-177. PubMed ID: 36849852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]